OncoMatch/Clinical Trials/NCT06007846
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
Is NCT06007846 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Namenda for hepatocellular carcinoma.
Treatment: Namenda — This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition to the primary endpoint and multiple secondary efficacy endpoints, we will describe changes in quality of life on treatment over time.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
adequate blood counts
Liver function
Child-Pugh cirrhosis score of B7 or greater; Child-Pugh A cirrhosis excluded
Cardiac function
Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina [excluded]
Patients must have a Child-Pugh cirrhosis score of B7 or greater and deemed not a candidate for aggressive systemic treatment. Patients must have adequate blood counts and organ function. Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Inova Schar Cancer Institute · Fairfax, Virginia
- Inova Health Care Service · Falls Church, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify